Transcatheter aortic valve replacement (TAVR) is a viable alternative to surgery in patients with severe symptomatic aortic stenosis. Owing to significant advances in TAVR technologies and expertise over the past few years, indications for TAVR have expanded to patients across the entire spectrum of surgical risk. Nonetheless, periprocedural and long-term thrombo-embolic complications remain frequent . Within this background, targeting the pathophysiological mechanisms related to platelet aggregation and thrombus formation with antiplatelets and/or anticoagulants seems imperative. Dual antiplatelet therapy (DAPT) constitutes the cornerstone of medical treatment after coronary stenting based on the findings of numerous randomized controlled trials (RCTs) conducted over the last two decades . The same paradigm has been initially translated to TAVR, despite inherent differences between the two procedures. In the absence of robust evidence from large RCTs, current clinical practices are heterogeneous and primarily based on expert consensus . Hence, DAPT typically included both a preprocessed loading (either a single dose within hours before TAVR or as an earlier start of the daily dose) but also as a longitudinal post-procedure treatment. Thereafter, we will explain why we should not mix these two very different ways of using DAPT periprocedurally.